StrataGraft approved by FDA

StrataGraft, a treatment for thermal burns that was developed from cells originally isolated and characterized in the laboratory of Pathology Professor Lynn Allen-Hoffmann at the University of Wisconsin School of Medicine and Public Health, has been approved for use by the FDA. Dr. Allen-Hoffmann’s initial discoveries led to founding a UW-Madison spin-out company, Stratatech Corporation in 2000. Stratatech continued work to develop advanced regenerative medicines such as StrataGraft. The company was purchased in 2016 by Mallinckrodt Pharmaceuticals based in the UK.

Read the full FDA news release:

StrataGraft and the StrataGraft logo are trademarks of a Mallinckrodt company.